Clinical and economic burden of idiopathic pulmonary fibrosis: A retrospective cohort study

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Raimundo, Karina ^a   Chang, Eunice ^b   Broder, Michael S ^b   Alexander, Kimberly ^a   Zazzali, James ^a   Swigris, Jeffrey J ^c  

^a GENENTECH INC   (United States)

^b PHAR   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

Health care costs; Health care resource utilization; Idiopathic pulmonary fibrosis

Indexed keywords

AGED; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FIBROSING ALVEOLITIS; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; RETROSPECTIVE STUDY; AMBULATORY CARE; ECONOMICS; FACTUAL DATABASE; HEALTH CARE COST; HOSPITALIZATION; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PREVALENCE; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84955636857     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0165-1     Document Type: Article

References (28)

1. Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP, et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014;89(8):1130-42.
2. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199-203.
3. Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev. 2013;22(129):281-91.
4. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J. 2011;37(4):743-6.
5. Lee AS, Mira-Avendano I, Ryu JH, Daniels CE. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med. 2014;108(7):955-67.
6. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest. 2005;127(1):284-94.
7. Collard HR, Ward AJ, Lanes S, Cortney HD, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829-35.
8. Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 2015; 1-9
9. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92.
10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
11. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllarniemi M. Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med. 2013;13:53.
12. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-6.
13. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483-92.
14. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176(3):277-84.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
16. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21(126):355-61.
17. Cohen R, Martinez M. Health insurance coverage: early release of estimates from the national health interview survey, 2012. March 2013.Available from: http://www.cdc.gov/nchs/nhis/releases.htm.
18. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-72.
19. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967-72.
20. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980-5.
21. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66(6):462-7.
22. Cleary PD, Mechanic D, Greenley JR. Sex differences in medical care utilization: an empirical investigation. J Health Soc Behav. 1982;23(2):106-19.
23. Verbrugge LM, Wingard DL. Sex differentials in health and mortality. Women Health. 1987;12(2):103-45.
24. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. J Fam Pract. 2000;49(2):147-52.
25. Optum. Real world health care experiences. 2015.Available from https://www.optum.com
26. Tkacz J, Ellis LA, Meyer R, Bolge SC, Brady BL, Ruetsch C. Quality process measures for rheumatoid arthritis: performance from members enrolled in a national health plan. J Manag Care Spec Pharm. 2015;21(2):135-43.
27. Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual. 2006;21(4):269-75.
28. Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med. 2012;7(1):42.